Gilead gets cancer drug from China-based Genhouse for $80M upfront
吉利德以8000万美元的预付款从manbetx3.0 公司勤浩医药获得一款抗癌药

Gilead is buying the global rights to an oral cancer drug from Genhouse Bio, a China-based biotech that filed for an IPO on the Hong Kong Stock Exchange last month.
吉利德正从勤浩医药手中收购一款口服抗癌药物的manbetx app苹果 权益。勤浩医药是一家总部位于manbetx3.0 的生物科技公司，上月已向香港交易及結算所有限公司递交首次公开募股申请。